In-Vivo CAR T Update With Umoja Biopharma's David Fontana, Ph.D.
Business Of Biotech
00:00
Emojia CAR-T Therapy: A Systemic Approach
In an ideal world, Emojia CAR-T therapy would be administered into the lymph nodes. We're also looking at subcutaneous administrations and other route of administration that's highly focused. And finally, I'm going to put a little plug in. Lupogen has this thing called extracorporeal delivery. What we can do with that is hook up a patient to the system. It basically collects the T-cells into their thing called the sidecar. The lentiviral particles, our VivaVek right into these little bags.
Transcript
Play full episode
